Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non Operating Income (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Non Operating Income for 7 consecutive years, with $525000.0 as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income rose 600.0% year-over-year to $525000.0; the TTM value through Mar 2026 reached -$2.2 million, down 132.74%, while the annual FY2025 figure was $16000.0, 99.76% down from the prior year.
  • Non Operating Income hit $525000.0 in Q1 2026 for Barinthus Biotherapeutics, up from -$3.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $6.7 million in Q4 2024 and bottomed at -$4.4 million in Q4 2023.
  • Average Non Operating Income over 5 years is $838437.5, with a median of $474500.0 recorded in 2025.
  • Year-over-year, Non Operating Income tumbled 191.57% in 2023 and then surged 1530.77% in 2025.
  • Barinthus Biotherapeutics' Non Operating Income stood at $4.8 million in 2022, then plummeted by 191.57% to -$4.4 million in 2023, then surged by 251.11% to $6.7 million in 2024, then tumbled by 152.28% to -$3.5 million in 2025, then skyrocketed by 115.0% to $525000.0 in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $525000.0, -$3.5 million, and $424000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.